Navigation Links
Aethlon Medical Discloses Cancer and Infectious Disease Therapy Presentation at ISEV 2013
Date:4/18/2013

tasis, and the development of drug resistance.  By addressing this unmet medical need, the Hemopurifier® is positioned as an adjunct to improve established cancer treatment regimens.

Certain statements herein may be forward-looking and involve risks and uncertainties.  Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating from either compassionate use or non-compassionate use of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or sepsis therapies or as a standalone cancer or hepatitis C therapy or standalone sepsis therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to p
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
2. Aethlon Medical Note: Marc Robins Joins the Aethlon Team
3. Aethlon Medical Note: Fiscal Year Revenue Guidance
4. Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
5. Aethlon Medical to Present at Todays Security Research Associates 8th Annual Growth Conference
6. Aethlon Medical (AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis
7. Aethlon Medical Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes
8. Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available
9. Aethlon Medical Announces the Appointment of Thomas V. Wornham and Philip A. Ward to its Board of Directors
10. Aethlon Medical Announces Renewal of DARPA Dialysis-Like Therapeutics Contract
11. Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  ResMed ... has signed a definitive agreement to acquire ... non-invasive ventilation and sleep-disordered breathing medical devices ... innovation and market reputation in China, combined with ResMed,s global leadership in sleep ... in China suffering ...
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... 2015  Unichem Pharmaceuticals ( USA ), ... tablets 25 mg 1000-count bottle to the consumer level. ... due to the identification of a Clopidogrel tablet found ... The risk associated with mistakenly taking a Clopidogrel tablet ... of experiencing Clopidogrel,s side effects which include bleeding and/or ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
... BRISBANE, Australia, Oct. 3, 2011 Ventus Medical ... Sleep Apnea Therapy, an innovative, non-invasive treatment for ... Australia and New Zealand. BMedical Pty. Ltd. will ... in these countries. (Photo:   http://photos.prnewswire.com/prnh/20110209/SF45785-a ...
... Oct. 3, 2011 PAREXEL International Corporation (NASDAQ: ... of Fiscal Year 2012 on Monday, October 31, 2011 after ... available on PAREXEL,s website at www.PAREXEL.com and on ... PAREXEL will host a conference call and live webcast at ...
Cached Medicine Technology:Ventus Medical Launches Provent® Sleep Apnea Therapy in Australia and New Zealand 2Ventus Medical Launches Provent® Sleep Apnea Therapy in Australia and New Zealand 3PAREXEL Announces Date of First Quarter Fiscal Year 2012 Earnings Release and Conference Call 2
(Date:7/30/2015)... ... July 30, 2015 , ... OSF Healthcare System has been ... Most Wired Survey conducted by Hospitals & Health Networks. This marks the fourth consecutive ... by The Sisters of the Third Order of St. Francis . , Health ...
(Date:7/30/2015)... ... 2015 , ... Women's dating coach Simone Myers has just ... interested in improving their love lives using specific "lines" designed to trigger powerful ... public early this morning, has drawn praise from several dating and relationship advice ...
(Date:7/30/2015)... ... July 30, 2015 , ... Eyepartner is ... victims in San Diego, California’s Gaslamp Quarter Plaza for five years this September. ... actively monitor the area for any suspicious activity. These cameras are in place ...
(Date:7/30/2015)... ... , ... Google recently announced that it will be disclosing any incidents involving ... June 8, 2015 article published by Nasdaq , the powerful tech company maintains ... computer-driven cars, which such industry players as Tesla CEO Elon Musk believe may very ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care ... Angeles, and San Bernardino counties, today announced that Dr. Michael Demoratz, PhD, LCSW, ... Demoratz is a strong proponent of early access to palliative care services for ...
Breaking Medicine News(10 mins):Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3
... ... sector. , ... Alberta (PRWEB) March 5, 2010 -- ANT Wireless ("ANT" www.thisisant.com ), a division ... A noted leader in the design and manufacturing of sport precision instruments, ...
... ... of Nevada, a Las Vegas-based healthcare organization, announced the acquisition of Rainbow Medical Center, an ... Rainbow Medical Center is now part of the Fremont Medical Centers Division of HealthCare Partners ... (PRWEB) March ...
... ... leading cause of mortality in the U.S., according to the Centers for Disease Control ... Charleston, ... problem. The culprit…Hospital Acquired Infections (HAIs) and they have generated much attention over the ...
... Mt. Everest Summiter (with ... race across the Sahara desert this April 2010. Gary is doing this to raise awareness and ... ... miles (in sections approximate to 25, 34, 38, 82, 42, 22 km) run over 6 days ...
... during the 39th Annual Meeting of the American ... E. Washington Convention Center in Washington, DC, lead ... present a poster of a study titled "TLR2 ... Reactivation." Although oral co-infections (e.g. periodontal disease) are ...
... ... the safety of the company,s products are taken very seriously. , , ... Bloomingdale, IL (PRWEB) March 4, 2010 -- ... to lead healthier lives. Product safety and quality are the company,s highest priorities; therefore any ...
Cached Medicine News:Health News:Suunto Joins ANT+ Interoperable Ecosystem 2Health News:Suunto Joins ANT+ Interoperable Ecosystem 3Health News:HealthCare Partners of Nevada and Rainbow Medical Center Join Forces 2Health News:24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 2Health News:24x7 Infection Control, Inc. Announces World's First, Modern “Shield” Against Microbial Contamination 3Health News:Mt. Everest Summiter Gary Guller (With One Arm) To Race Across Sahara in "The World's Toughest Stage Race" 2Health News:Mt. Everest Summiter Gary Guller (With One Arm) To Race Across Sahara in "The World's Toughest Stage Race" 3Health News:Periodontal pathogens enhance HIV-1 promoter activation in T cells 2Health News:NOW Foods Response to Fish Oil and PCB Concerns 2
Rapid latex agglutination test for presumptive identification of E. coli serogroup O157:H7 isolates. Colorimetric with red O157 latex and blue H7 latex....
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
... The Directigen™ Meningitis Individual Tests ... tests for the direct qualitative ... influenzae type b, S. pneumoniae, ... Escherichia coli K1 in cerebrospinal ...
Medicine Products: